MerLion Pharmaceuticals Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
- Investors
-
14
MerLion Pharmaceuticals General Information
Description
Developer of anti-bacterial drugs designed for combating serious bacterial infections. The company focuses on developing next-generation fluoroquinolone with properties that can treat different infections even within the intracellular compartments of infected macrophages, enabling healthcare providers to address antibiotic-resistant infections with high efficacy and safety.
Contact Information
Website
www.merlionpharma.comCorporate Office
- Robert-Rossle-Strasse 10
- 13125 Berlin
- Germany
Corporate Office
- Robert-Rossle-Strasse 10
- 13125 Berlin
- Germany
MerLion Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 16-Apr-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 18-May-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 28-Apr-2022 | Completed | Clinical Trials - Phase 2 | |||
| 4. Grant | 28-Jun-2017 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 13-Jul-2010 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series B) | 01-Mar-2007 | $30M | $43.5M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 30-Oct-2002 | $13.5M | $13.5M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MerLion Pharmaceuticals Comparisons
Industry
Financing
Details
MerLion Pharmaceuticals Competitors (18)
One of MerLion Pharmaceuticals’s 18 competitors is Volastra, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Volastra | Venture Capital-Backed | New York, NY | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Ona Therapeutics | Venture Capital-Backed | Barcelona, Spain | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Vicore Pharma Holding | Formerly VC-backed | Stockholm, Sweden |
MerLion Pharmaceuticals Patents
MerLion Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| DE-102015100068-A1 | Finafloxacin for use in the treatment of harnway infections | Inactive | 06-Jan-2015 | ||
| EP-3242667-A1 | Finafloxacin for use in the treatment of urinary tract infections | Active | 06-Jan-2015 | ||
| EP-3242667-B1 | Finafloxacin for use in the treatment of urinary tract infections | Active | 06-Jan-2015 | ||
| EP-3242667-C0 | Finafloxacin for use in the treatment of urinary tract infections | Active | 06-Jan-2015 | ||
| ES-2981965-T3 | Finafloxacin for use in the treatment of urinary tract infections | Active | 06-Jan-2015 | A61K31/5383 |
MerLion Pharmaceuticals Signals
MerLion Pharmaceuticals Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Denk Pharma | Corporation | Minority | ||
| Defense Threat Reduction Agency | Government | |||
| Rosetta Capital (UK) | Venture Capital | Minority | ||
| Vi Partners | Venture Capital | Minority | ||
| Brandenburg Kapital | Venture Capital | Minority |
MerLion Pharmaceuticals Acquisitions (2)
MerLion Pharmaceuticals’s most recent deal was a Merger/Acquisition with Athelas (Drug Delivery). The deal was made on 21-Aug-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Athelas (Drug Delivery) | 21-Aug-2006 | Merger/Acquisition | Drug Discovery | ||
| Combinature Biopharm | 21-Aug-2006 | Merger/Acquisition | Drug Discovery |
MerLion Pharmaceuticals FAQs
-
When was MerLion Pharmaceuticals founded?
MerLion Pharmaceuticals was founded in 2000.
-
Where is MerLion Pharmaceuticals headquartered?
MerLion Pharmaceuticals is headquartered in Berlin, Germany.
-
What is the size of MerLion Pharmaceuticals?
MerLion Pharmaceuticals has 10 total employees.
-
What industry is MerLion Pharmaceuticals in?
MerLion Pharmaceuticals’s primary industry is Drug Discovery.
-
Is MerLion Pharmaceuticals a private or public company?
MerLion Pharmaceuticals is a Private company.
-
What is MerLion Pharmaceuticals’s current revenue?
The current revenue for MerLion Pharmaceuticals is .
-
How much funding has MerLion Pharmaceuticals raised over time?
MerLion Pharmaceuticals has raised $50.5M.
-
Who are MerLion Pharmaceuticals’s investors?
Denk Pharma, Defense Threat Reduction Agency, Rosetta Capital (UK), Vi Partners, and Brandenburg Kapital are 5 of 14 investors who have invested in MerLion Pharmaceuticals.
-
Who are MerLion Pharmaceuticals’s competitors?
Volastra, Gesynta Pharma, Ona Therapeutics, Melinta Therapeutics, and Vicore Pharma Holding are some of the 18 competitors of MerLion Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process